Skip to main content

Table 2 Anticoagulation parameters and reversal agents administered

From: Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study

Agents PCC3 (n = 57) PCC4 (n = 23)
PCC dose
 Dose (units) 2000 (1530–2500) 2595 (1880–3307)
 Dose by weight (units/kg) 21.5 (20.4–25.9) 29.3 (25.9–37.3)
 Dose by pre-PCC INR (units/INR) 645.2 (438.3–982.8) 674.3 (576.5–870.0)
 Dose by weight/pre-PCC INR (units/kg/INR) 7.9 (5.6–10.5) 8.2 (7.0–10.2)
INR
 INR prior to reversal 2.8 (2.1–4.1) 3.7 (2.6–4.9)
 INR post first dose 1.7 (1.5–2.0) 1.3 (1.3–1.4)
 INR change pre to post 1.1 (0.6–2.0) 2.3 (1.2–3.3)
Time (minutes)
 Minutes from pre-PCC INR to dose given 78 (56.0–113.0) 73 (40.0–108.5)
 Minutes from dose given to post-PCC INR (6 h or less) 93 (46.0–228.0) 226 (156.5–368.5)
 Minutes from pre- to post-PCC INR (12 h or less) 215 (133.0–326.0) 296 (241.0–483.0)
Vitamin K routes, n (%)
 Intravenous 36 (63.2%) 21 (91.3%)
 Oral 9 (15.8%) 1 (4.3%)
 Subcutaneous 4 (7.0%) 0 (0.0%)
 None 8 (14.0%) 1 (4.3%)
Vitamin K given during stay (mg) 5.0 (2.0–10.0) 10.0 (7.5–10.0)
FFP given during stay (yes/no), n (%) 34 (59.6%) 7 (30.4%)
 Units given in those receiving FFP (range) (1–12) (1–6)
FFP given between INR 1 and 2 (yes/no), n (%) 15 (26.3%) 2 (8.7%)
 Units given in those receiving FFP (range) (1–4) (1, 2)
RBC given during stay (yes/no), n (%) 21 (36.8%) 7 (30.4%)
 Units given in those receiving RBC (range) (1–12) (1–4)
  1. Median (25th–75th percentiles) given unless specified, FFP fresh frozen plasma, INR international normalized ratio, PCC prothrombin complex concentrate, PCC3 3-factor PCC, PCC4 4-factor PCC, RBC red blood cells